PLUR
Pluri·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 1
Bearish signal 0
Ample Liquidity
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About PLUR
Pluri Inc.
A developer of stem cell therapy products to treat multiple ischemic and inflammatory conditions
Biological Technology
05/11/2001
12/10/2007
NASDAQ Stock Exchange
127
06-30
Common stock
MATAM Advanced Technology Park, Building No. 5, Haifa, Israel 3508409
Engaged in the research, development, manufacturing, clinical trials and business development of cell therapy and related technologies.
Pluri Inc., a Nevada corporation, was registered on May 11, 2001. The biotechnology company relies on a proprietary cell amplification platform to develop scalable cell-based solutions covering the healthcare, food and agriculture sectors. Through a network of collaborative enterprises, the company promotes a diversified pipeline of products and services, covering categories such as cultivated food, regenerative medicine and cell-based raw materials. At the same time, the company has built a unique three-dimensional (" 3 D ") cell expansion technology platform, and has built an industrial-scale cell production facility that conforms to Good Manufacturing Practices (" GMP ") standards (currently using a self-declared compliance model). Its technology has been applied in the fields of regenerative medicine, immunotherapy, food technology, contract development and production organization (CDMO) and agricultural technology (AgTech). In the future, it plans to expand its technology to more industries and verticals that require large-scale and cost-effective cell augmentation solutions through cooperation, joint ventures, license agreements and other cooperation modes.
Company Financials
EPS
PLUR has released its 2025 Q4 earnings. EPS was reported at -0.98, versus the expected -0.73, missing expectations. The chart below visualizes how PLUR has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
PLUR has released its 2026 Q1 earnings report, with revenue of 316.00K, reflecting a YoY change of -3.07%, and net profit of -6.13M, showing a YoY change of -1.59%. The Sankey diagram below clearly presents PLUR's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
